UBS Keeps Neutral Rating on Treace Medical Concepts (TMCI)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2025
0mins
Source: NASDAQ.COM
UBS Coverage and Price Forecast: UBS has maintained a Neutral recommendation for Treace Medical Concepts (TMCI) as of November 7, 2025, with an average one-year price target of $8.67/share, indicating a potential upside of 94.39% from its current price of $4.46/share.
Projected Revenue and EPS: Treace Medical Concepts is projected to achieve annual revenue of $266 million, reflecting a 21.55% increase, while the expected non-GAAP EPS is -0.59.
Fund Sentiment and Ownership Changes: There are 257 funds reporting positions in TMCI, with a slight decrease in ownership by 3.02% over the last quarter. The average portfolio weight for these funds is 0.08%, which has increased by 1.55%.
Shareholder Activity: Notable changes in shareholder allocations include Armistice Capital increasing its stake by 0.78%, while CIBC Private Wealth Group and Jpmorgan Chase significantly reduced their holdings by 35.91% and 89.97%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMCI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMCI
Wall Street analysts forecast TMCI stock price to rise
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 3.080
Low
3.00
Averages
4.87
High
7.50
Current: 3.080
Low
3.00
Averages
4.87
High
7.50
About TMCI
Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
Treace Medical Q1 Earnings Beat Expectations
- Earnings Highlights: Treace Medical Concepts reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in a loss position.
- Revenue Performance: The company generated $47.2 million in revenue for Q1, a 10.3% year-over-year decline, yet it exceeded expectations by $1.15 million, demonstrating resilience in sales amid market challenges.
- Gross Profit and Margin: Gross profit for Q1 was $37.4 million, down from $41.9 million in Q1 2025, with gross margin slightly decreasing from 79.7% to 79.3%, reflecting cost pressures impacting profitability.
- Operating Expense Control: Total operating expenses for Q1 were $54.6 million, a decrease of $2.9 million compared to the same period last year, showcasing effective cost management measures that contribute to improving overall financial health.
See More
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Treace Medical Concepts Q4 2025 Earnings Call Insights
- Revenue Performance: Q4 2025 revenue was $62.5 million, a 9% year-over-year decline primarily due to a shift towards lower-priced products, indicating increased competitive pressure in the market.
- Cash Flow Management: As of December 31, 2025, the company had $48.4 million in cash and cash equivalents, with a new credit facility providing an additional $115 million in liquidity, ensuring operational stability for the coming years.
- Future Outlook: The company projects full-year 2026 revenue between $200 million and $212 million, facing a potential 6% decline; however, management remains optimistic about Q4 growth driven by new product launches and increased case volumes.
- Profitability Improvement: Adjusted EBITDA loss for 2025 decreased to $3.9 million from $11 million in 2024, indicating positive progress in cost control and operational efficiency.
See More
Treace Medical Reports Q4 Results and 2026 Guidance
- Earnings Report: Treace Medical Concepts reported a Q4 GAAP EPS of -$0.15, aligning with expectations, while revenue of $62.5 million, down 9% year-over-year, exceeded forecasts by $0.63 million, indicating ongoing market challenges for the company.
- 2026 Revenue Guidance: The company is projecting 2026 revenue between $200 million and $212 million, representing a decline of 6% to 0% compared to 2025, reflecting pressures from weak market demand and intensified competition.
- Adjusted EBITDA Outlook: Treace anticipates an adjusted EBITDA loss of $4 million to $6 million for 2026, compared to a loss of $3.9 million in 2025, highlighting ongoing challenges in restoring profitability.
- Debt Financing Plan: The company announced a debt facility of up to $175 million, aimed at enhancing liquidity and supporting future operational and growth strategies.
See More
Treace Medical Reports 2025 Financial Highlights
- Revenue Growth: Treace Medical reported fourth-quarter revenue of $62.5 million and full-year revenue of $212.7 million, marking a 2% increase year-over-year; however, fourth-quarter revenue decreased by 9% compared to 2024, primarily due to a shift towards lower-priced product sales impacting overall revenue performance.
- Net Loss Situation: The company recorded a net loss of $9.4 million in the fourth quarter and $59.0 million for the full year 2025, an increase from 2024, although adjusted EBITDA loss was reduced by 64%, indicating efforts in cost control and operational efficiency.
- Cash Usage Reduction: Cash usage decreased by 46% to $27.3 million in 2025, reflecting improved financial management, with expectations of a further 50% reduction in cash usage for 2026, providing better funding for future growth initiatives.
- Market Expansion: By the end of 2025, the number of active surgeons increased by 202 to a total of 3,337, representing 33% of U.S. surgeons performing bunion surgeries, indicating significant progress in market penetration and customer base expansion.
See More
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
Treace Medical Q1 Earnings Beat Expectations
- Earnings Highlights: Treace Medical Concepts reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in a loss position.
- Revenue Performance: The company generated $47.2 million in revenue for Q1, a 10.3% year-over-year decline, yet it exceeded expectations by $1.15 million, demonstrating resilience in sales amid market challenges.
- Gross Profit and Margin: Gross profit for Q1 was $37.4 million, down from $41.9 million in Q1 2025, with gross margin slightly decreasing from 79.7% to 79.3%, reflecting cost pressures impacting profitability.
- Operating Expense Control: Total operating expenses for Q1 were $54.6 million, a decrease of $2.9 million compared to the same period last year, showcasing effective cost management measures that contribute to improving overall financial health.
See More
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Treace Medical Concepts Q4 2025 Earnings Call Insights
- Revenue Performance: Q4 2025 revenue was $62.5 million, a 9% year-over-year decline primarily due to a shift towards lower-priced products, indicating increased competitive pressure in the market.
- Cash Flow Management: As of December 31, 2025, the company had $48.4 million in cash and cash equivalents, with a new credit facility providing an additional $115 million in liquidity, ensuring operational stability for the coming years.
- Future Outlook: The company projects full-year 2026 revenue between $200 million and $212 million, facing a potential 6% decline; however, management remains optimistic about Q4 growth driven by new product launches and increased case volumes.
- Profitability Improvement: Adjusted EBITDA loss for 2025 decreased to $3.9 million from $11 million in 2024, indicating positive progress in cost control and operational efficiency.
See More
Treace Medical Reports Q4 Results and 2026 Guidance
- Earnings Report: Treace Medical Concepts reported a Q4 GAAP EPS of -$0.15, aligning with expectations, while revenue of $62.5 million, down 9% year-over-year, exceeded forecasts by $0.63 million, indicating ongoing market challenges for the company.
- 2026 Revenue Guidance: The company is projecting 2026 revenue between $200 million and $212 million, representing a decline of 6% to 0% compared to 2025, reflecting pressures from weak market demand and intensified competition.
- Adjusted EBITDA Outlook: Treace anticipates an adjusted EBITDA loss of $4 million to $6 million for 2026, compared to a loss of $3.9 million in 2025, highlighting ongoing challenges in restoring profitability.
- Debt Financing Plan: The company announced a debt facility of up to $175 million, aimed at enhancing liquidity and supporting future operational and growth strategies.
See More
Treace Medical Reports 2025 Financial Highlights
- Revenue Growth: Treace Medical reported fourth-quarter revenue of $62.5 million and full-year revenue of $212.7 million, marking a 2% increase year-over-year; however, fourth-quarter revenue decreased by 9% compared to 2024, primarily due to a shift towards lower-priced product sales impacting overall revenue performance.
- Net Loss Situation: The company recorded a net loss of $9.4 million in the fourth quarter and $59.0 million for the full year 2025, an increase from 2024, although adjusted EBITDA loss was reduced by 64%, indicating efforts in cost control and operational efficiency.
- Cash Usage Reduction: Cash usage decreased by 46% to $27.3 million in 2025, reflecting improved financial management, with expectations of a further 50% reduction in cash usage for 2026, providing better funding for future growth initiatives.
- Market Expansion: By the end of 2025, the number of active surgeons increased by 202 to a total of 3,337, representing 33% of U.S. surgeons performing bunion surgeries, indicating significant progress in market penetration and customer base expansion.
See More
